Tonix Pharmaceuticals Holding Corp. (TNXP)

Latest News

View all news

Dec 5, 2022

Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in Animals

Dec 1, 2022

Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress

Nov 30, 2022

Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress

View all news

Summary Investor Presentation December 2022

View Presentation

Special Meeting of Shareholders

View Event Add to Calendar View All Events

Latest Financial Results

Q3 2022

Quarter Ended Sep 30, 2022

Earnings Release

PDF HTML

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

IR Contacts

Company

Tonix Pharmaceuticals Holding Corp.
26 Main Street
Suite 101
Chatham, NJ 07928
T: 862-799-8599
investor.relations@tonixpharma.com

Investor Relations

TONIX Pharmaceuticals
investor.relations@tonixpharma.com

Transfer Agent

VStock Transfer, LLC
77 Spruce Street
Suite 201
Cedarhurst, NY 11516
T: 212-828-8436
https://www.vstocktransfer.com

Tonix is enrolling participants in a Phase 3 trial for fibromyalgia, the RESILIENT study. For more information, please visit www.resilientstudy.com or www.clinicaltrials.gov (NCT05273749).

Investor Relations

Latest News

Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in Animals

Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress

Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress

Latest Presentation

Upcoming Event

Latest Financial Results

Q3 2022

Latest Annual Filing

IR Contacts

Company

Investor Relations

Transfer Agent

Investor Relations

Latest News

Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in Animals

Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress

Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress

Latest Presentation

Upcoming Event

Latest Financial Results

Q3 2022

Latest Annual Filing

Report Links

Email Alerts

Stock Snapshot

IR Contacts

Company

Investor Relations

Transfer Agent